A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (Q65351997)
Jump to navigation
Jump to search
clinical trial
Language | Label | Description | Also known as |
---|---|---|---|
English | A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) |
clinical trial |
Statements
CIMPASI-2 (English)
0 references
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis (English)
0 references
15 December 2014
0 references
5 January 2016
0 references
227
0 references
18 year
0 references